^
    Back
    Association details:
    Biomarker:PD-L2 overexpression
    Cancer:Melanoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Immunother Cancer
    Title:

    Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

    Excerpt:
    Transcript levels were significantly higher in responders (CR/PR/SD) than in nonresponders (PD) for CD8A (p = 0.0001) and IRF1 (p = 0.0019). PFS was strongly associated with high CD274 (p = 0.0046), PDCD1LG2 (p = 0.0039), CD8A (p = 0.0002), and IRF1 (p = 0.0030) mRNA expression.
    DOI:
    https://doi.org/10.1186/s40425-019-0731-9